Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Roberts Glore & Co. Inc. IL

Roberts Glore & Co. Inc. IL lessened its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,088 shares of the pharmaceutical company’s stock after selling 67 shares during the period. Roberts Glore & Co. Inc. IL’s holdings in Vertex Pharmaceuticals were worth $1,646,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Dunhill Financial LLC raised its stake in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the last quarter. Brown Lisle Cummings Inc. purchased a new stake in Vertex Pharmaceuticals during the 4th quarter worth about $30,000. Legacy Investment Solutions LLC purchased a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $33,000. Truvestments Capital LLC purchased a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $35,000. Finally, Sugar Maple Asset Management LLC purchased a new stake in Vertex Pharmaceuticals during the 4th quarter worth about $35,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on VRTX. HC Wainwright reiterated a “buy” rating and set a $550.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Citigroup began coverage on Vertex Pharmaceuticals in a research report on Thursday, November 14th. They set a “buy” rating and a $575.00 price objective for the company. Bank of America dropped their price objective on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research report on Thursday, December 19th. Finally, Oppenheimer cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 19th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $506.70.

Vertex Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ:VRTX opened at $488.29 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The stock has a market capitalization of $125.39 billion, a P/E ratio of -221.95, a PEG ratio of 2.11 and a beta of 0.41. The stock has a 50-day simple moving average of $448.27 and a 200-day simple moving average of $461.32.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Ourania Tatsis sold 530 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the transaction, the executive vice president now directly owns 58,539 shares of the company’s stock, valued at approximately $27,825,928.26. The trade was a 0.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 1,084 shares of company stock valued at $505,512. Corporate insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.